Author:
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 155 | 106 | 3 |
| Full Text Views | 2 | 0 | 0 |
| PDF Downloads | 4 | 0 | 0 |
Treatment of Schistosoma Mekongi with Praziquantel: a Double-Blind Study
T. E. Nash
T. E. Nash
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20205
Search for other papers by T. E. Nash in
Current site
Google Scholar
PubMed
Search for other papers by T. E. Nash in
Current site
Google Scholar
PubMed
M. Hofstetter
M. Hofstetter
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20205
Search for other papers by M. Hofstetter in
Current site
Google Scholar
PubMed
Search for other papers by M. Hofstetter in
Current site
Google Scholar
PubMed
A. W. Cheever
A. W. Cheever
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20205
Search for other papers by A. W. Cheever in
Current site
Google Scholar
PubMed
Search for other papers by A. W. Cheever in
Current site
Google Scholar
PubMed
E. A. Ottesen
E. A. Ottesen
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20205
Search for other papers by E. A. Ottesen in
Current site
Google Scholar
PubMed
Search for other papers by E. A. Ottesen in
Current site
Google Scholar
PubMed
Praziquantel is a newly developed drug effective in the treatment of schistosomiasis. In order to assess the efficacy and toxicity of praziquantel in the treatment of Schistosoma mekongi, 11 infected Laotian refugees, all belonging to a single extended family, were treated in a double-blind crossover trial with praziquantel and placebo. Initially, one group of five received praziquantel 60 mg/kg body weight in three divided doses orally while the remainder received an identically appearing placebo. Patients were evaluated clinically before, during and following therapy for 2 days. After 2.5 months the patients were re-evaluated and subjected to the opposite treatment, and final follow-up took place 5–7 months later. Three other patients were treated using an open protocol. All but one person was cured (91%). This patient failed to show a decrease in egg excretion 2.5 weeks after praziquantel therapy and was lost to follow-up thereafter. Side effects were common and consisted primarily of abdominal pain, malaise, and fever. These were generally mild and transient. No abnormal laboratory findings were associated with praziquantel therapy. At the final evaluation 6/6 patients with initial hepatomegaly showed a decrease in liver size.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 155 | 106 | 3 |
| Full Text Views | 2 | 0 | 0 |
| PDF Downloads | 4 | 0 | 0 |